Approved Equities, Voluntary Recall, and New Product Launches - Analyst Notes on Baxter, Agilent, InterMune, Intuitive Surgical, and Mindray

NEW YORK, March 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Agilent Technologies Inc. (NYSE: A), InterMune Inc. (NASDAQ: ITMN), Intuitive Surgical, Inc. (NASDAQ: ISRG), and Mindray Medical International Ltd (NYSE: MR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Baxter International Inc. Analyst Notes

On March 5, 2014, Baxter International Inc. (Baxter) initiated a voluntary recall of a single lot of DIANEAL PD-2 Peritoneal Dialysis Solution with 1.5% Dextrose 6000mL (Ambu-Flex II) to the hospital/user level in the United States. According to Baxter, the recall was due to mold caused by a leak in the container. The Company has sent notifications by recall letter instructing customers to locate and remove any affected product from their facility. All patients who received product from the affected lot also were contacted by recall letter and provided instructions to arrange for product return. Dialysis centers, facilities, distributors and patients should stop use and return to place of purchase. According to the Company, the affected lot was distributed to customers between May 2013 and January 2014. The full analyst notes on Baxter International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/BAX/report.pdf

--

Agilent Technologies Inc. Analyst Notes

On March 11, 2014, Agilent Technologies Inc. (Agilent) introduced the world's highest-performance oscilloscope - the Infiniium Z-Series oscilloscope. The Z-Series can be synchronized to simultaneously measure up to 40 channels with a maximum of 63-GHz real-time oscilloscope bandwidth (on up to 10 oscilloscopes). "The Z-Series further solidifies Agilent's leadership in the high-end oscilloscope market," said Jay Alexander, Vice President and General Manager of Agilent's Oscilloscope and Protocol Division. "With its processing power and new user interface, the new series helps engineers bring products using emerging technologies to market significantly faster. Several Z-Series oscilloscopes have already been deployed around the world and are now the go-to instrument in those laboratories." The Z-Series offers 10 models ranging from 20-60 GHz, all of which are bandwidth-upgradable to 63 GHz. The full analyst notes on Agilent Technologies Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/A/report.pdf

--

InterMune Inc. Analyst Notes

On March 11, 2014, shares of InterMune Inc. (InterMune) slipped 1.37% to end trading at $33.18. Over the past five-day trading period, InterMune's stock jumped 4.49%, while the Nasdaq Composite dipped by 1.03% during that same period. The full analyst notes on InterMune Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/ITMN/report.pdf

--

Intuitive Surgical, Inc. Analyst Notes

On March 11, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced that the Compensation Committee of its Board of Directors approved equity awards to 26 new employees. The 26 employees were granted a combination of Restricted Stock Units (RSUs) and Stock Options to purchase an aggregate of 3,134 shares of the Company's common stock; 2,389 of the shares granted were Stock Options and 745 of the shares granted were RSUs. Both the RSUs and Stock Options vest over four years. The Stock Options expire in 10 years assuming continued employment. No officers received any award under this plan, and the exercise price for the Stock Options granted was $443.98. The equity awards were granted under the Company's 2009 Commencement Incentive Plan which was adopted by the Board for the granting of equity awards to new employees. The full analyst notes on Intuitive Surgical, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/ISRG/report.pdf

--

Mindray Medical International Ltd Analyst Notes

On March 7, 2014, Mindray Medical International Ltd (Mindray) announced that its ADS' holders of record as of March 14, 2014 are entitled to the recently declared dividend of $0.50 per ordinary share, payable on or around April 8, 2014. Each Mindray ADS corresponds to one ordinary share. The record date for Mindray's ordinary shares (previously announced as March 8, 2014) will also be March 14, 2014. The Company also announced that dividends paid to its ADS holders via the depositary bank will be subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. The full analyst notes on Mindray Medical International Ltd are available to download free of charge at:

http://www.AnalystsReview.com/03142014/MR/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED